Clinical trials: Cardiotoxicity, active
Breast Cancer
Evaluating 6-months of HER2-targeted Therapy in Patients With HER2 Positive Early-stage Breast Cancer That Achieve a Pathological Complete Response to Neoadjuvant Systemic Therapy
The activity of trastuzumab in early-stage, HER2-positive breast cancer, has been demonstrated in many studies, with meta-analyses showing that in combination with a variety of chemotherapy backbones, trastuzumab reduces the risk…
- Trial name
- NCT04928261
- Testing
- Trastuzumab
- Where
- Canada
- Volunteers
- 52 people
- Sponsor
- Ottawa Hospital Research Institute
Anthracycline-induced Cardiac Toxicity, Lymphoma
REmote iSchemic condItioning in Lymphoma PatIents REceiving ANthraCyclinEs
Multinational, prospective, proof of concept phase II, double-blinded, sham-controlled, randomized clinical trial (RCT) to evaluate the efficacy and safety of Remote Ischaemic PreConditioning (RIPC) in Lymphoma patients receiving…
- Trial name
- RESILIENCE (NCT05223413)
- Testing
- RIPC
- Where
- 24 sites in Denmark, France and 4 more
- Volunteers
- 608 people
- Sponsor
- Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III
Triple Negative Breast Cancer
NeoCARD: Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer Patients
This is a single-arm Phase II study to assess the efficacy of a 12-18 week neoadjuvant carboplatin, paclitaxel, and pembrolizumab (CPP) regimen in a response-adaptive manner for triple-negative breast cancer (TNBC) patients who…
- Trial name
- NeoCARD (NCT06845319)
- Testing
- Carboplatin, Paclitaxel, Pembrolizumab
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Medical University of South Carolina
Non-small Cell Lung Cancer, Cardiac Toxicity
Evaluation of Impedance Cardiography for Assessing Hemodynamic Shifts in Patients With LA-NSCLC During Treatment.
This study aimed to investigate the role of impedance cardiography (ICG) in evaluating hemodynamic changes during the 6-minute walk test (6MWT) in patients with locally advanced non-small cell lung cancer (LA-NSCLC) who underwent…
- Trial name
- NCT06277388
- Testing
- Impedance cardiography
- Where
- China
- Volunteers
- 231 people
- Sponsor
- Sun Yat-sen University
Cardiac Toxicity, Cancer
Cardiovascular Health in Adult Patients With Cancer Exposed to Cardiotoxic Therapies
The goal of this observational study is to evaluate the cardiovascular health and prognosis of adult patients with cancer, treated with cardiotoxic therapies.
- Trial name
- CV_CANCER (NCT06664528)
- Testing
- ECHOCARDIOGRAPHY, ELECTROCARDIOGRAPHY (ECG), LABORATORY TESTS
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Anthracycline Related Cardiotoxicity in Breast Cancer
Protective Effects of the Nutritional Supplement Sulforaphane on Doxorubicin-Associated Cardiac Dysfunction
Cardiomyopathy is a major complication of doxorubicin (DOX) chemotherapy, and 10-21% of breast cancer patients receiving DOX experience compromised cardiac function.
- Trial name
- NCT03934905
- Testing
- sulforaphane
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Texas Tech University Health Sciences Center
Breast Cancer Females
Chronic Impacts of Endocrine Therapy on Cardiovascular and Brain Health Outcomes in Breast Cancer
Aromatase inhibitors are the most used endocrine therapy for hormone-positive breast cancer. Despite the evidence that aromatase inhibitor therapy is associated with increased risk of cardiovascular events, potentially related to…
- Trial name
- STRIVE-Chronic (NCT06776458)
- Testing
- N/A - Usual Care
- Where
- Canada
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- University of Toronto
Cardiotoxicity, Cardiac Biomarkers
Cardiac Biomarkers in Patients Receiving Immune Checkpoint Inhibitors (PRIME-ICI)
Immune checkpoint inhibitors (ICIs) are widely used cancer treatments. Blood tests such as cardiac troponin and N-terminal pro-B-type natriuretic peptide (NT-proBNP) can help clinicians investigate possible heart injury, but…
- Conditions
- Cardiotoxicity, Cardiac Biomarkers, Cancer
- Trial name
- PRIME-ICI (NCT07864727)
- Where
- United Kingdom
- Volunteers
- 300 people
- Sponsor
- South Tees Hospitals NHS Foundation Trust
Neoplasms
Determinants of Physical Activity Level in Pediatric Oncological Patients Treated With Cardiotoxic Therapy - a Study Protocol
Cancer treatment in children is generally effective, but unfortunately, it often comes with side effects-unwanted negative impacts.
- Trial name
- NCT06256068
- Volunteers
- 300 people
- Sponsor
- Medical University of Warsaw
Breast Cancer (Early Breast Cancer), Cardiotoxicity
Cardiac Side Effects of Systemic Therapy in Early-Stage Breast Cancer
The goal of this observational study is to evaluate cardiac side effects in women with early-stage breast cancer who receive systemic chemotherapy and/or anti-HER2 therapy as part of their standard cancer care.
- Conditions
- Breast Cancer (Early Breast Cancer), Cardiotoxicity, Cancer Therapy-Related Cardiac Dysfunction
- Trial name
- C-BREAST-01 (NCT07588425)
- Where
- Turkey (Türkiye)
- Volunteers
- 100 people
- Sponsor
- Fatih GURLER
Cardiac Toxicity, Early-stage Breast Cancer
Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted
This study proposes that the addition of statins reduces the treatment delays or early discontinuations secondary to cardiotoxicity in patients with Stage I-III HER2 positive breast being treated with anti-HER2 therapy.
- Trial name
- NCT05559164
- Testing
- Lipitor 40mg Tablet
- Where
- 10 sites in United States
- Volunteers
- 60 people
- Sponsor
- Rutgers, The State University of New Jersey
Immune Checkpoint Inhibitors, Cardiotoxicity
Cardiac Magnetic Resonance Monitoring of Immune Checkpoint Inhibitor-related Cardiotoxicity
This study is a prospective cohort clinical research that analyzes the changes in CMR parameters before and after immune checkpoint inhibitors (ICIs) therapy in patients with gynecologic malignancies.
- Trial name
- NCT06132984
- Testing
- Cardiac magnetic resonance
- Where
- China
- Volunteers
- 22 people
- Sponsor
- West China Second University Hospital
Cardiac Dysfunction, Cardiovascular Diseases
Cardiac Dysfunction in Childhood Cancer Survivors
This multicenter, prospective cohort study evaluates early cardiac dysfunction in adult survivors of childhood cancer. The hypothesis of this study is that cardiac dysfunction can be detected earlier when using speckle tracking…
- Conditions
- Cardiac Dysfunction, Cardiovascular Diseases, Childhood Cancer
- Trial name
- Cardio-Onco (NCT03790943)
- Testing
- cardiac assessment
- Where
- 6 sites in Switzerland
- Volunteers
- 500 people
- Sponsor
- University of Bern
Cardiotoxicity
Early Identification of Cardivascular Damage Induced by Chemotherapy and Antineoplastic Treatments in Pediatric Age
To test whether the implementation of new diagnostic techniques (ultrasonography, speckle tracking, vascular stiffness study, cardiac MRI, and histologic studies) allows in CAYA (Childern, Adolescents, and Young Adults) cancer…
- Trial name
- PREDICT (NCT07382141)
- Testing
- Parameters of vascular stiffness
- Where
- 5 sites in Italy
- Volunteers
- 400 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Ventricular Ejection Fraction, LVF
AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Assessment Using COR ECG Wearable Monitor
This prospective, multicenter, cluster-randomized controlled study aims to evaluate the accuracy of an investigational artificial intelligence (AI) Software as a Medical Device (SaMD) designed to compute ejection fraction (EF)…
- Conditions
- Ventricular Ejection Fraction, LVF, LV Dysfunction, Atrial Enlargement
- Trial name
- EFACT (NCT06699056)
- Testing
- 15-minutes of sitting during COR ECG Acquistion
- Where
- 8 sites in United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Peerbridge Health, Inc
Cardiotoxicity, HER2/Neu Positive
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
This trial has two cohorts of patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. All patients must be receiving trastuzumab-based treatment.
- Conditions
- Cardiotoxicity, HER2/Neu Positive, Metastatic Malignant Neoplasm in the Brain, Recurrent Breast Carcinoma
- Trial name
- NCT03418961
- Testing
- Carvedilol, Laboratory Biomarker Analysis, Patient Observation
- Where
- 590 sites in United States, Puerto Rico and 2 more
- Volunteers
- 491 people
- Sponsor
- SWOG Cancer Research Network
Multiple Myeloma
Cardiac Toxicity and Prognostic Value of New Echocardiographic Indicators in the Treatment of Primary Multiple Myeloma
Multiple myeloma (MM) is a malignant proliferative plasma cell disease, which accounts for approximately 10% and ranks secondly of hematological malignancies in many countries.
- Trial name
- NCT06039735
- Testing
- Chemotherapy and/or autologous hematopoietic stem cell transplantation
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Qilu Hospital of Shandong University
Breast Cancer, Anthracycline Related Cardiotoxicity in Breast Cancer
Cardiovascular Health Education Via Virtual Reality for Breast Cancer Survivors Receiving Anthracyclines or Trastuzumab
The main goal of this study is to test a virtual reality (VR) program, Survivors' Virtual Reality Survivorship Experience (SurviVRSE), designed to help Breast Cancer survivors (n=30) learn about heart health.
- Conditions
- Breast Cancer, Anthracycline Related Cardiotoxicity in Breast Cancer, Virtual Reality, Trastuzumab
- Trial name
- NCT07426913
- Testing
- Cardiovascular Health Education and Gaming through Virtual Reality
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Virginia Commonwealth University
Breast Cancer, Hematologic Malignancy
Global Cardio Oncology Registry
G-COR is the first Global Prospective Cardio-Oncology Registry. It is a multinational, multicenter prospective observational cohort registry, with the goal of collecting clinical, laboratory, imaging, demographic, and…
- Conditions
- Breast Cancer, Hematologic Malignancy, Immune Checkpoint Inhibitor-Related Myocarditis, Cardiotoxicity
- Trial name
- G-COR (NCT05598879)
- Testing
- anonymized data collection during programmed surveillance clinical follow up
- Where
- United States
- Volunteers
- 5,000 people
- Sponsor
- The Cleveland Clinic
Cancer, Anticancer Treatment
Risk Prediction Scores for Cardiotoxicity in Cancer Patients Treated With Cardiotoxic Anticancer Therapies in Europe
Cancer management has undergone major advances over the past 30 years. Several anticancer therapies are now highly effective, allowing many cancers to become chronic diseases through sequential lines of treatment.
- Conditions
- Cancer, Anticancer Treatment, Cardiovascular Disease Risk Factor, Cardiovascular Diseases
- Trial name
- EUCARTOXSCORES (NCT07621289)
- Testing
- antineoplastic agents, endocrine therapy, immunostimulants drugs (ATC classification)
- Volunteers
- 10,000 people
- Sponsor
- University Hospital, Caen